Research programme: mitochondrial Complex I disease therapies - BioElectron Technology

Drug Profile

Research programme: mitochondrial Complex I disease therapies - BioElectron Technology

Alternative Names: EPI B0001; EPI C0001; EPI-761

Latest Information Update: 14 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer BioElectron Technology
  • Class
  • Mechanism of Action Electron transport complex I modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Friedreich's ataxia; MELAS syndrome; Optic atrophy

Most Recent Events

  • 01 Aug 2018 Edison Pharmaceuticals is now called BioElectron Technology
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in MELAS-syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top